Tracey W. Tsang, Daniel H. Rosenblatt, Indra Parta, Elizabeth J. Elliott
{"title":"Estimating the Prevalence of Fetal Alcohol Spectrum Disorder in Australia","authors":"Tracey W. Tsang, Daniel H. Rosenblatt, Indra Parta, Elizabeth J. Elliott","doi":"10.1111/dar.14082","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Fetal alcohol spectrum disorder (FASD) is caused by prenatal alcohol exposure (PAE) and characterised by severe neurodevelopmental impairment. Australian studies have reported PAE prevalence of between 14% and 78% of births. Estimating national FASD prevalence in the general population using gold-standard active case ascertainment is costly and time-consuming, and alternative approaches are required.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using a published equation for the risk of FASD following PAE (estimated from an international meta-analysis) and a pooled estimate of PAE prevalence in Australia (from a meta-analysis of 78 studies reporting 16 large general population-based birth cohorts between 1975 and 2018), we estimated the population prevalence of FASD. Monte Carlo simulations were used to determine confidence intervals.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Estimated FASD prevalence in the general population was 3.64% (95% confidence interval 2.91%, 4.41%).</p>\n </section>\n \n <section>\n \n <h3> Discussion and Conclusions</h3>\n \n <p>The estimated FASD prevalence in the general population of Australia was comparable to that in other high-income countries (e.g., USA, Canada). Although it is likely that certain vulnerable populations have significantly higher FASD prevalence, this estimate provides a baseline estimate for the general population to inform service development and strategies for prevention of FASD and guide future research.</p>\n </section>\n </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"44 5","pages":"1522-1525"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.14082","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol review","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dar.14082","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Fetal alcohol spectrum disorder (FASD) is caused by prenatal alcohol exposure (PAE) and characterised by severe neurodevelopmental impairment. Australian studies have reported PAE prevalence of between 14% and 78% of births. Estimating national FASD prevalence in the general population using gold-standard active case ascertainment is costly and time-consuming, and alternative approaches are required.
Methods
Using a published equation for the risk of FASD following PAE (estimated from an international meta-analysis) and a pooled estimate of PAE prevalence in Australia (from a meta-analysis of 78 studies reporting 16 large general population-based birth cohorts between 1975 and 2018), we estimated the population prevalence of FASD. Monte Carlo simulations were used to determine confidence intervals.
Results
Estimated FASD prevalence in the general population was 3.64% (95% confidence interval 2.91%, 4.41%).
Discussion and Conclusions
The estimated FASD prevalence in the general population of Australia was comparable to that in other high-income countries (e.g., USA, Canada). Although it is likely that certain vulnerable populations have significantly higher FASD prevalence, this estimate provides a baseline estimate for the general population to inform service development and strategies for prevention of FASD and guide future research.
期刊介绍:
Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying alcohol, tobacco and drug problems. Contributors to the Journal examine and report on alcohol and drug use from a wide range of clinical, biomedical, epidemiological, psychological and sociological perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective. However, all philosophies will find a place in the Journal: the principal criterion for publication of papers is their quality.